# AEON Biopharma (AEON) — News

AEON · AMEX · Stock

Canonical page: https://www.lighthorse.io/tickers/aeon/news

## Recent headlines

- [AEON still sees FY oper income 340.00 byen, est. 327.16B yen](https://www.ainvest.com/news/aeon-sees-fy-oper-income-340-00-byen-est-327-16b-yen-2610) — AInvest Wire, Oct 13, 2026
  AEON Co., Ltd., the Japanese retail and financial services giant, has reaffirmed its full-year operating income forecast of 340.00 billion yen, despite recent estimates suggesting a slightly lower figure of 327.16 billion yen. The company’s confidence in meeting its target comes amid a 20%…
- [AEON still sees FY net income 73.00B yen, est. 71.99B yen](https://www.ainvest.com/news/aeon-sees-fy-net-income-73-00b-yen-est-71-99b-yen-2610) — AInvest Wire, Oct 13, 2026
- [AEON Stores continuing connected transactions master pact](https://www.ainvest.com/news/aeon-stores-continuing-connected-transactions-master-pact-2610) — AInvest Wire, Oct 12, 2026
  AEON Stores, a subsidiary of Japan-based Aeon Group, continues its strategic collaboration under a master partnership agreement with Ocado Solutions, a UK-based technology and logistics provider specializing in online grocery fulfillment. The partnership, initially announced in November 2019…
- [AEON-Destinus joint low-cost interceptors proposal selected for U.S. Army Xtech | Apex intercept finals](https://www.ainvest.com/news/aeon-destinus-joint-cost-interceptors-proposal-selected-army-xtech-apex-intercept-finals-2610) — AInvest Wire, Sep 30, 2026
  The U.S. Army has selected the AEON-Destinus joint proposal for low-cost interceptors as part of its Xtech initiative, marking a significant development in defense procurement. The selection follows a competitive evaluation process, with the proposal advancing to the Apex intercept finals. This…
- [AEON Biopharma - To initiate CMAP pharmacodynamic study in Q1 2027](https://www.ainvest.com/news/aeon-biopharma-initiate-cmap-pharmacodynamic-study-q1-2027-2609) — AInvest Wire, Sep 30, 2026

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).